Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (3y) (2014 - 2026)
Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 1,301.00 |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 331.00 |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -667.00 |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 480.00 |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -254.00 |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1,342.00 |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 1,902.00 |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -96.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,342.00 |
| Dec 31, 2025 | 222.00 |
| Sep 30, 2025 | 912.00 |
| Jun 30, 2025 | 1,158.00 |
| Mar 31, 2025 | 1,156.00 |
| Dec 31, 2024 | 1,259.00 |
| Sep 30, 2024 | 740.00 |
| Jun 30, 2024 | 1,072.00 |
| Mar 31, 2024 | 906.00 |
| Dec 31, 2023 | -91.00 |
| Sep 30, 2023 | -558.00 |
| Jun 30, 2023 | -2,379.00 |
| Mar 31, 2023 | -1,284.00 |
| Dec 31, 2022 | 382.00 |
| Sep 30, 2022 | 238.00 |
| Jun 30, 2022 | 265.00 |
| Mar 31, 2022 | 696.00 |
| Dec 31, 2021 | 149.00 |
| Sep 30, 2021 | 573.00 |
| Jun 30, 2021 | 1,160.00 |